IRCT20220928056051N1
Completed
Phase 3
Comparing the effect of Empagliflozin with Pioglitazone on nonalcoholic fatty liver in diabetic type 2 patients treated with metformin
Oroumia University of Medical Sciences0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Oroumia University of Medical Sciences
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 20 to 75 years
- •Type 2 diabetes
- •A hemoglobin A1C (HbA1c) between 7 and 10
- •Body mass index (BMI) between 20 to 40 kg/m2
- •Treated with metformin for at least three months with a minimum dose of 1500 mg daily
- •?At least grade 1 of non\-alcoholic fatty liver disease (NAFLD)
Exclusion Criteria
- •Patients receiving drugs that stimulate insulin secretion, or insulin
- •Type 1 diabetes
- •Patients treated with diabetes drugs including sitagliptin and liraglutide
- •Glomerular Filtration Rate (GFR) less than 30
- •Uncontrolled or aggravated heart disease (class 3 and 4\)
- •Liver diseases including autoimmune hepatitis and viral hepatitis
- •Alcohol consumption of more than 140 cc for women and 250 cc for men per week
- •breastfeeding
- •History of recurrent urinary tract infection
- •Bladder Cancer
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105
Not yet recruiting
Phase 2
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
Recruiting
Phase 2
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesCardiomyopathyK75.81IRCT20190122042450N5Iran University of Medical Sciences70
Not yet recruiting
Phase 2
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81IRCT20190122042450N1Iran University of Medical Sciences100
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90